Key keywords: Novo Nordisk, semaglutide, alcohol use disorder, LX9851, chronic pain treatment, pharmaceutical pipeline expansion, phase 2 clinical trial, GLP-1 receptor agonist, diabetic peripheral neuropathic pain, unmet medical need Danish pharmaceutical giant Novo Nordisk announced two major additions to its late-stage clinical pipeline this week, launching a phase 2a study of its blockbuster GLP-1 agonist semaglutide for alcohol use disorder (AUD) and a phase 2 trial of its novel oral candidate LX9851 for diabetic peripheral neuropathic pain (DPNP). The semaglutide AUD trial will enroll 270 adult patients diagnosed with moderate to severe AUD across 38 clinical sites in North America and Western Europe. Participants will be randomized to receive either 2.4 mg of once-weekly semaglutide, the same dose approved for chronic weight management, or a placebo over a 40-week treatment period. The trial’s primary endpoints will measure percentage change in average daily alcohol consumption and the proportion of patients achieving complete abstinence from alcohol during the final 12 weeks of treatment. Preclinical studies and retrospective real-world data have previously suggested that GLP-1 agonists may reduce cravings for alcohol and other addictive substances by modulating reward pathways in the brain, marking the first time Novo Nordisk has formally tested semaglutide for an addiction-related indication. Topline results from the trial are expected in the first half of 2026. Parallel to the semaglutide AUD study, Novo Nordisk’s LX9851 phase 2 trial will assess the safety, tolerability and efficacy of three different dose levels of the oral T-type calcium channel blocker in 320 adults living with DPNP, a chronic pain condition affecting up to 50% of patients with long-term diabetes. Unlike existing pain management options that carry risks of dependence, sedation or severe gastrointestinal side effects, LX9851 is designed to target pain signaling pathways directly without impacting central nervous system function. Topline results for this trial are expected in the fourth quarter of 2025. The two new trials mark a key expansion of Novo Nordisk’s pipeline beyond its core metabolic indications of type 2 diabetes and obesity, as the company looks to capture share of high-growth, high-unmet-need therapeutic areas. Industry analysts estimate that a semaglutide AUD indication could add up to $12 billion in annual global sales for the company if approved, while a successful LX9851 launch could capture up to 8% of the $85 billion global chronic pain market by 2030. The moves also come as Novo Nordisk faces growing competition from other GLP-1 developers, making pipeline diversification a core strategic priority for the brand over the next five years.